ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Ranibizumab Control

Its studies are mostly in Macular Degeneration, led by AbbVie.

Furthest: phase 3, since May 28, 20251 company-led study, 1 open or runningNext primary completion: Mar 2033 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie11 open or runningphase 3since May 28, 2025May 28, 2025Mar 2033phase 3 · NCT07007065

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 28, 2025First study: phase 3 study in Neovascular Age-related Macular DegenerationFirst studyNCT07007065 · 561 planned · United States, Austria, Belgium and more

Ahead

  1. Mar 2033Primary completion: phase 3 study in Neovascular Age-related Macular DegenerationNCT07007065

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07007065Neovascular Age-related Macular Degeneration · United States, Austria, Belgium and more3RecruitingMar 2033561

How it is read

Names in the registry

  • “Ranibizumab Control”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.